Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Radboud university medical center, Nijmegen, Netherlands

In this page

How to contact the center

Full member

HCP Center

The main aim is to have a significant impact on healthcare. This mission is accomplished by:The Radboud university medical center (Radboudumc, in short) offers patients top-clinical and top-referral care and have an important social role in increasing and sharing knowledge and expertise. It wants to take the lead or at least actively contribute to the development of reliable, innovative and affordable healthcare. It focuses on the health of man and society in the Netherlands as well as abroad.

Delivering verifiable high-quality
Offering participatory and personalized healthcare
Using our resources efficiently
Participating in sustainable, professional networks in every area

The Ophthalmology department of the Radboudumc is a top tertiary center for various eye diseases, and is a leading expert in the treatment and management of retinal diseases. Besides daily clinical care, we research diseases of the retina. The main goals of our research are to better understand the molecular basis of these diseases, and to develop new diagnostic devices and therapies.
The Human Genetics department of the Radboudumc performs groundbreaking research into the relationship between genes and diseases. Patient care (division clinical genetics) and genetic diagnostics (division genome diagnostics) performed within the department of Human Genetics is hosted by an official and acclaimed Centre for Clinical Genetics.

Picture : .Koen

Contact

Radboud university medical center, Nijmegen, Netherlands

Geert Grooteplein Zuid 10
6525 GA Nijmegen
Netherlands

Team

Pr Carel HOYNG

Representative

Netherlands

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Suzanne Yzer

Substitute

Netherlands

See more

Pr Frans Cremers

Netherlands

Genetic Diagnostics (TWG6), Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Franca HARTGERS

Substitute

Netherlands

See more

Clinical trials

NCT05537220 - Active, Not recruiting

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

Interventional
See the trial
voir la fiche
NCT05158296 - Active, Not recruiting

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Interventional
See the trial
voir la fiche

NCT05698316 - Recruiting, Active

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression: (INTERCEPT-AMD)

Observational
See the trial
voir la fiche
NCT05633576 - Completed

Steroid Eye Drops Versus Placebo Eye Drops in Chronic Central Serous Chorioretinopathy Trial (PICS Trial)

Interventional
See the trial
voir la fiche
NCT04671433 - Active, Not recruiting

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Interventional
See the trial
voir la fiche
NCT04794101 - Active, Not recruiting

Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Interventional
See the trial
voir la fiche
NCT04127006 - Active, Not recruiting

Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS).

Observational
See the trial
voir la fiche
NCT03913143 - Active, Not recruiting

A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).

Interventional
See the trial
voir la fiche
NCT03359551 - Completed

Natural History of the Progression of Choroideremia Study NSR-CHM-OS1.

Observational
See the trial
voir la fiche
NCT03146078 - Active, Not recruiting

Rate of Progression in USH2A Related Retinal Degeneration

Observational
See the trial
voir la fiche
NCT03584165 - Recruiting, Active

A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Interventional
See the trial
voir la fiche
NCT03079141 - Unknown

Half-dose photodynamic therapy versus eplerenone treatment in chronic centralserous chorioretinopathy.

Interventional
See the trial
voir la fiche
NCT02771379 - Completed

A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON).

Observational
See the trial
voir la fiche
NCT04770545 - Active, Not recruiting

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Interventional
See the trial
voir la fiche
NCT04765345 - Active, Not recruiting

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher

Observational
See the trial
voir la fiche
NCT04926129 - Completed

Natural history of the progression of X-linked retinitis pigmentosa.

Observational
See the trial
voir la fiche